Cargando…
A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir
Anti-influenza drugs play major roles in the management of severe influenza infections. Neuraminidase inhibitors (NAIs), which are active against all influenza A subtypes and the 2 major influenza B lineages, constitute the only class of antivirals recommended for the control of influenza epidemics...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569976/ https://www.ncbi.nlm.nih.gov/pubmed/28852674 http://dx.doi.org/10.1093/ofid/ofx105 |
_version_ | 1783259089973805056 |
---|---|
author | Abed, Yacine Boivin, Guy |
author_facet | Abed, Yacine Boivin, Guy |
author_sort | Abed, Yacine |
collection | PubMed |
description | Anti-influenza drugs play major roles in the management of severe influenza infections. Neuraminidase inhibitors (NAIs), which are active against all influenza A subtypes and the 2 major influenza B lineages, constitute the only class of antivirals recommended for the control of influenza epidemics and eventual pandemics. Thus, the emergence of NAI resistance could be a major clinical concern. Although most currently circulating influenza A and B strains are susceptible to NAIs, clinical cases of influenza viruses harboring single or multiple NA substitutions or deletions conferring a cross-resistance phenotype to the 2 main NAIs (oseltamivir and zanamivir) have been reported, mostly in immunocompromised individuals. Moreover, such events seem to be more frequent in A(H1N1)pdm09 viruses containing the H274Y substitution together with other NA changes (I222R, E119D/G). This review summarizes the therapeutic regimens leading to the emergence of NAI cross-resistant influenza A and B viruses as well as the virologic properties of such variants. |
format | Online Article Text |
id | pubmed-5569976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55699762017-08-29 A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir Abed, Yacine Boivin, Guy Open Forum Infect Dis Review Article Anti-influenza drugs play major roles in the management of severe influenza infections. Neuraminidase inhibitors (NAIs), which are active against all influenza A subtypes and the 2 major influenza B lineages, constitute the only class of antivirals recommended for the control of influenza epidemics and eventual pandemics. Thus, the emergence of NAI resistance could be a major clinical concern. Although most currently circulating influenza A and B strains are susceptible to NAIs, clinical cases of influenza viruses harboring single or multiple NA substitutions or deletions conferring a cross-resistance phenotype to the 2 main NAIs (oseltamivir and zanamivir) have been reported, mostly in immunocompromised individuals. Moreover, such events seem to be more frequent in A(H1N1)pdm09 viruses containing the H274Y substitution together with other NA changes (I222R, E119D/G). This review summarizes the therapeutic regimens leading to the emergence of NAI cross-resistant influenza A and B viruses as well as the virologic properties of such variants. Oxford University Press 2017-05-18 /pmc/articles/PMC5569976/ /pubmed/28852674 http://dx.doi.org/10.1093/ofid/ofx105 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Review Article Abed, Yacine Boivin, Guy A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir |
title | A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir |
title_full | A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir |
title_fullStr | A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir |
title_full_unstemmed | A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir |
title_short | A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir |
title_sort | review of clinical influenza a and b infections with reduced susceptibility to both oseltamivir and zanamivir |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569976/ https://www.ncbi.nlm.nih.gov/pubmed/28852674 http://dx.doi.org/10.1093/ofid/ofx105 |
work_keys_str_mv | AT abedyacine areviewofclinicalinfluenzaaandbinfectionswithreducedsusceptibilitytobothoseltamivirandzanamivir AT boivinguy areviewofclinicalinfluenzaaandbinfectionswithreducedsusceptibilitytobothoseltamivirandzanamivir AT abedyacine reviewofclinicalinfluenzaaandbinfectionswithreducedsusceptibilitytobothoseltamivirandzanamivir AT boivinguy reviewofclinicalinfluenzaaandbinfectionswithreducedsusceptibilitytobothoseltamivirandzanamivir |